Skip to Content

'
David J. McConkey, Ph.D.

Present Title & Affiliation

Primary Appointment

Director of Urological Research, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1989 Karolinska Institute, Stockholm, Sweden, PHD, Biochemical Toxicology
1986 Brown University, Providence, RI, BA, Biochemistry and American History

Postgraduate Training

1/1990-6/1993 Research Fellow, Harvard Medical School, Dept. of Pathology, Dana-Farber Cancer Inst., Laboratory of Immunobiology, Boston, MA, Ellis L. Reinherz, M.D.
5/1987-7/1987 Guest Researcher, Brown University, Department of Biochemistry, Providence, RI, David L. Brautigan, Ph.D.
9/1986-11/1989 Graduate Student in Biochemical Toxicology, Karolinska Institute, Departments of Toxicology and Immunology, Stockholm, Sweden, Sten Orrenius, MD.
6/1985-8/1986 Research Assistant, University of Minnesota School of Medicine, Department of Pharmacology, Minneapolis, MN, Jordan L. Holtzman, M.D., Ph.D.
2/1985-5/1985 Research Assistant, Rhode Island Hospital, Department of Orthopaedics and Brown University, Department of Biochemistry, Providence, RI, John Sandy, Ph.D.
6/1983-9/1984 Research Assistant, University of Minnesota School of Medicine, Department of Biochemistry, Minneapolis, MN, Mary E. Dempsey, Ph.D.

Honors and Awards

2003 Award for Research Excellence, UT M.D. Anderson Cancer Center
2003 Finalist, Julie and Ben Rogers Award for Excellence
2002 Educator of the Month, M. D. Anderson Cancer Center
2001-2003 HSC Honors Convocation Recipient
2001 John P. McGowen Outstanding Teacher Award, University of Texas Health Science Center, GSBS
1991-1993 Cancer Research Institute Fellowship
1986 American Scandinavian Foundation Fellowship

Professional Memberships

American Society of Clinical Oncology
Member, 2008-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Dickstein RJ, Nitt G, Dinney CP, Davies BR, Kamat A, McConkey DJ. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther. In Press.
2. Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. J Surg Res. 176(1):147-53, 7/2012.
3. Marquis L, Tran M, Choi W, Lee IL, Huszar D, Siefker-Radtke A, Dinney C, McConkey DJ. P63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther. 13(7):477-86, 5/2012. PMID: 22361733.
4. Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, Yu D, Adam L, Wen S, Shen Y, Dinney C, McConkey DJ, Siefker-Radtke A. P63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One 7(1):e30206, 1/2012. PMCID: PMC3254658.
5. Lopez G, Torres K, Liu J, Hernandez B, Young E, Belousov R, Bolshakova S, Lazar A, Slopis JM, McCutcheon IE, McConkey DJ, Lev DC. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res 71(1). e-Pub 11/2011. PMCID: PMC3064267.
6. Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmil RM, Drabkin HA, Lloyd GK, Neuteboom ST,McConkey DJ, Palladino MA, Spear MA. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. e-Pub 11/2011. PMID: 22080430.
7. Ni CT, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore VG, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334(6059):1129-1133, 11/2011. PMCID: PMC3280949.
8. Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. J Surg Res. e-Pub 10/2011. PMID: 22099584.
9. McConkey DJ. RAIDDing ER Stress for oncolytic viral therapy. Cancer Cell 20(4):416-418, 10/2011. PMID: 22014566.
10. Santos FP, Kantarjian H, McConkey D, O'Brien S, Faderi S, Borthakur G, Ferrajoli A, Wright J, Cortes J. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. Clin Lymphoma Myeloma Leuk 11(4):355-360, 8/2011. PMID: 2181637.
11. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 6(6):e20636, 6/2011. PMCID: PMC3113804.
12. Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE, Wang H, McConkey DJ, Hwang R, Logsdon C, Abbruzzesse J, Fleming JB. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol. e-Pub 6/2011. PMID: 21701930.
13. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 17(8):528-539, 5/2011. PMID: 21587219.
14. Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris LD, Urbauer DL, McConkey DJ, Dickstein RJ, Cheng T, Grossman HB,. Effects of mTOR inhibitor everolimus (RAD001)bladder cancer cells. Clin Can Res 17(9), 5/2011. e-Pub 3/2011. PMID: 21415218.
15. Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Frenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA. Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 11(3):254-284, 3/2011. PMID: 21247382.
16. Shah JB, McConkey DJ, Dinney CP. New strategies in muscle invasive bladder cancer: On the road to personalized medicine. Clin Cancer Res 17(9). e-Pub 3/2011. PMID: 21415213.
17. Black PC, Brown GA, Dinney CP, Kassouf W, Inamoto T, Arora A, Gallagher D, Munsell MF, Bar-Eli M, McConkey DJ, Adam L. Receptor heterodimerization: A new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol 185(2):693-700, 2/2011.
18. Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM. Bladder cancer stem cells. Curr Stem Cell Res Ther 5(4):387-395, 12/2010. PMID: 20955163.
19. Black PC, Shetty A, Brown GA, Esparza-Coss E, Metwalli AR, Argarwal PK, McConkey DJ Hazle JD, Dinney CP. Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU Int 106(11):1799-1804, 12/2010. PMID: 20500508.
20. Metwalli AR, Khanbolooki S, Jinesh G, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM. Smac mimetic reverses resistance to TRAIL and chemotherapy in human cancer cells. Cancer Biol Ther. 10(9). e-Pub 11/2010. PMID: 20814238.
21. Svatek RS, Shah JB, Xing J, Chang D, Lin J, McConkey DJ, Wu X, Dinney CP. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer 116(19):4513-4519, 10/2010. e-Pub 6/2010. PMID: 20572047.
22. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C, Czerniak B. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol 28(4):429-440, 7/2010. PMCID: PMC2901550.
23. Zhu K, Dunner K, McConkey DJ. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 29(3):451-62, 1/2010. PMCID: PMC2809784.
24. McConkey DJ. Proteasome and HDAC: Who's zooming who? Blood 116(3):308-309, 2010.
25. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28(3-4):335-44, 12/2009. PMID: 20012924.
26. McConkey DJ, Dinney CP. The molecular, the bad, and the ugly: preventing bladder cancer via mTOR inhibition. Cancer Prev Res 2(12):1001-2, 12/2009. PMID: 19952365.
27. McConkey DJ, Dinney C. Urological Cancers. Cancer Metastasis Rev 28(3-4):267, 12/2009. PMID: 20013034.
28. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15(16):5060-5072, 8/2009. e-Pub 2009.
29. McConkey DJ. Bortezomib paradigm shift in myeloma. Blood 114(5):931-932, 7/2009. PMID: 19643992.
30. Fisher M, Zhang X-Q, McConkey DJ, Benedict WF. Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon cx:possible use as a surrogate marker. Cancer Gene Therapy 16(7):567-72, 7/2009. PMID: 19197325.
31. Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, Lev DC. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 15(10):3472-3483, 5/2009. PMID: 19417021.
32. Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ. Control of HlF-1alpha expression by elF2 alpha phosphorylation-mediated translational repression. Cancer Res 69(5):1836-1843, 2009. PMID: 19244104.
33. Haddad Y, Choi W, McConkey DJ. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res. 15(2):532-42, 2009. PMID: 19147758.
34. Raut CP, Takamori RK, Davis DW, Sweeney-Gotsch B, O'Reilly MS, McConkey DJ. Direct effects of recombinant human endostatin on tumor cell lL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer. Cancer Biol Ther 8(10), 2009. PMID: 19597326.
35. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69(14):5820-5828, 2009. PMID: 19584296.
36. Majewski T, Lee S, Jeong J, Yoon D, Kram A, Kim M, Tuziak T, Bondaruk J, Lee S, Park W, Tang KS,Chung W, Shen L, Ahmed SS, Johnston DA, Grossman HB, Dinney CP, Zhou J, Harris RA, Snyder C, Filipek S, Narod SA, Watson P, Lynch HT, Gazdar A, Bar-Eli M, Wu XF, McConkey DJ, Baggerly K, Issa J, Benedict WF, Scherer SE, Czerniak B. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest 88(7):694-721, 7/2008. PMCID: PMC2849658.
37. McConkey DJ. 20S ways to apoptosis. Nat Chem Biol 4(9):528-9, 2008. PMID: 18711380.
38. McConkey DJ. A novel role for a familiar protein in apoptosis induced by proteasome inhibition. Cancer Cell 14(1):1-2, 2008.
39. Zhou J, Zhang XQ, Ashoori F, McConkey DJ, Knowles MA, Dong L, Benedict WF. Early RB94-produced cytotoxicity in cancer cells is independent of caspase activation or 50 kb DNA fragmentation. Cancer Gene Ther, 2008.
40. Pino MS, Balsamo M, Di Modugno F, Mottolese M, Alessio M, Melucci E, Milella M, McConkey DJ, Philippar U, Gertler FB, Natali PG, Nistico P. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. Clin Cancer Res 14(15):4943-50, 2008.
41. Kassouf W, Brown GA, Black PC, Fisher MB, Inamoto T, Luongo T, Gallagher D, BAr-Eli M, McConkey DJ, Adam L, Dinney CP. Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol. 180(3):1146-53, 2008.
42. McConkey DJ, Zhu K. Mechanism of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 11(4-5):164-79, 2008. PMID: 18818117.
43. Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood, 2008.
44. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD. Nuclear factor-kappaB p65/reIA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 14(24):8143-51, 2008. PMID: 19088029.
45. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE,Bedikian AY, Camacho LH,Ross MI, Cormier JN, Gershenwald JE, Lee JE,Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99(5):734-40, 2008. PMID: 18728664.
46. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 14(5):1478-86, 2008.
47. Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, Benedict WF. Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther 14:241-250, 3/2007. PMID: 17096027.
48. Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, Benedict WF, Dinney CP. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol 177(5):1900-1906, 2007.
49. Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18(8):1400-1407, 2007.
50. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 5(12):3032-3041, 2007.
51. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B, Dinney CP. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 179(1):353-358, 2007.
52. Agarwal PK, Black PC, McConkey DJ, Dinney CP. Emerging drugs for targeted therapy of bladder cancer. Expert Opin Emerg Drugs 12(3):435-448, 2007.
53. Lee S, Jeong J, Majewski T, Scherer SE, Kim MS, Tuziak T, Tang KS, Baggerly K, Grossman HB, Zhou JH, Shen L, Bondaruk J, Ahmed SS, Samanta S, Spiess P, Wu X, Filipek S, McConkey D, Bar-Eli M, Issa JP, Benedict WF, Czerniak B. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci USA 104(34):13732-13737, 2007.
54. Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 67(4):1430-1435, 2007.
55. Papageorgiou A, Dinney CP, McConkey DJ. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther 6(6):872-879, 2007.
56. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP, McConkey DJ. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 6(1):227-285, 2007.
57. Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M, Chandra J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110(1):267-277, 2007.
58. Villares GJ, Zigler M, Blehm K, Bogdan C, McConkey D, Colin D, Bar-Eli M. Targeting EGFR in bladder cancer. World J Urol 25(6):573-579, 2007. PMID: 17690890.
59. Papageorgiou A, Dinney CP, McConkey DJ. Terferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther 6(6):872-879, 2007.
60. McConkey DJ. Therapy-induced apoptosis in primary tumors. Adv Exp Med Biol 608:31-51, 2007.
61. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 5:3032-3041, 12/2006. PMID: 17172406.
62. Walterscheid JP, Nghiem DX, Kazimi N, Nutt LK, McConkey DJ, Norval M, Ullrich SE. Cis-urocanic acid, a sunlight-induced immunosuppressive factor, activates immune suppression via the 5-HT2A receptor. Proc Natl Acad Sci U S A 103:17420-17425, 11/2006. PMID: 17085585.
63. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 5:2251-2260, 9/2006. PMID: 16985059.
64. Canfield SE, Zhu K, Williams SA, McConkey DJ. Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther 5:2043-2050, 8/2006. PMID: 16928825.
65. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 12:4671-4677, 8/2006. PMID: 16899617.
66. Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, McConkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 5:1836-1843, 7/2006. PMID: 16891470.
67. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K, Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 66:3773-3781, 4/2006. PMID: 16585204.
68. Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res 66:3802-3812, 4/2006. PMID: 16585207.
69. Carew JS, Nawrocki ST, Krupnik YV, Dunner K, Jr, McConkey DJ, Keating MJ, Huang P. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 107:222-231, 1/2006. PMID: 16144803.
70. Trevino JG, Gray MJ, Nawrocki ST, Summy JM, Lesslie DP, Evans DB, Sawyer TK, Shakespeare WC, Watowich SS, Chiao PJ, McConkey DJ, Gallick GE. Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis 9:101-110, 2006. PMID: 16871430.
71. Carew JS, Nawrocki ST, Krupnik YV, Dunner K, Jr, McConkey DJ, Keating MJ, Huang P. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 107:222-231, 2006. PMID: 16144803.
72. Nawrocki ST, Carew JS, Dunner K, Jr, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 65:11510-11519, 12/2005. PMID: 16357160.
73. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K, Jr, Huang P, Abbruzzese JL, McConkey DJ. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65:11658-11666, 12/2005. PMID: 16357177.
74. Pino MS, Nawrocki ST, Cognetti F, Abruzzese JL, Xiong HQ, McConkey DJ. Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biol Ther 4:1263-1269, 11/2005. PMID: 16319525.
75. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 65:10524-10535, 11/2005. PMID: 16288045.
76. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 65:4902-4908, 6/2005. PMID: 15930312.
77. Nutt LK, Gogvadze V, Uthaisang W, Mirnikjoo B, McConkey DJ, Orrenius S. Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis. Cancer Biol Ther 4:459-467, 4/2005. PMID: 15846091.
78. Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res 11:678-689, 1/2005. PMID: 15701856.
79. McConkey D, Nawrocki ST, Andtbacka R. Velcade displays promising activity in primary effusion lymphoma cells. Cancer Biol Ther 4:491-492, 2005.
80. Raut CP, Nawrocki S, Lashinger LM, Davis DW, Khanbolooki S, Xiong H, Ellis LM, McConkey DJ. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther 3:1217-1224, 12/2004. PMID: 15477758.
81. Carew JS, Nawrocki ST, Xu RH, Dunner K, McConkey DJ, Wierda WG, Keating MJ, Huang P. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia 18:1934-1940, 12/2004. PMID: 15483672.
82. Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict W, Dinney CP, McConkey DJ. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res 64:8973-8979, 12/2004. PMID: 15604261.
83. Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 10:525-532, 9/2004. PMID: 15336652.
84. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10:5732-5740, 9/2004. PMID: 15355900.
85. Raut CP, Takamori RK, Davis DW, Sweeney-Gotsch B, O'Reilly MS, McConkey DJ. Direct effects of recombinant human endostatin on tumor cell IL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer. Cancer Biol Ther 3:679-687, 7/2004. PMID: 15197351.
86. Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res 64:4601-2610, 7/2004. PMID: 15231672.
87. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3:279-290, 3/2004. PMID: 15026548.
88. Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej CA, Abbruzzese JL. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 22:459-466, 2004.
89. Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, Younes A. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin's disease cell lines is independent of inhibitor of nuclear factor-kB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10:3207-3215, 2004.
90. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Patel G, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10:3371-3376, 2004.
91. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 10:33-42, 2004. PMID: 14734449.
92. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3:59-70, 2004. PMID: 14749476.
93. Williams SA, McConkey DJ. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 63:7338-7344, 11/2003. PMID: 14612532.
94. Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 9:4570-4577, 10/2003. PMID: 14555532.
95. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2:835-843, 9/2003. PMID: 14555702.
96. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ, Bar-Eli M. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res 9:3167-3175, 8/2003. PMID: 12912969.
97. Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, McConkey DJ, Dinney CP. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 9:2786-2797, 7/2003. PMID: 12855659.
98. Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res 9:955-960, 3/2003. PMID: 12631592.
99. Zhang X, Multani AS, Zhou JH, Shay JW, McConkey D, Dong L, Kim CS, Rosser CJ, Pathak S, Benedict WF. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res 63:760-765, 2003.
100. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 9:33-41, 2003. PMID: 12602766.
101. Yang P, Collin P, Madden T, Chan D, Sweeney-Gotsch B, McConkey D, Newman RA. Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate 55:281-291, 2003.
102. Cao XX, Mohuiddin I, Chada S, Mhashilkar AM, Ozvaran MK, McConkey DJ, Miller SD, Daniel JC, Smythe WR. Adenoviral transfer of mda-7 leads to BAX up-regulation and apoptosis in mesothelioma cells, and is abrogated by over-expression of BCL-XL. Mol Med 8:869-876, 12/2002. PMID: 12606823.
103. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1:1243-1253, 12/2002. PMID: 12516957.
104. Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 21:7797-7807, 11/2002. PMID: 12420216.
105. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1:989-997, 10/2002. PMID: 12481421.
106. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804-3814, 9/2002. PMID: 12228200.
107. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792-3803, 9/2002. PMID: 12228199.
108. Guo Z, Clydesdale G, Cheng J, Kim K, Gan L, McConkey DJ, Ullrich SE, Zhuang Y, Su B. Disruption of Mekk2 in mice reveals an unexpected role for MEKK2 in modulating T-cell receptor signal transduction. Mol Cell Biol 22:5761-5768, 8/2002. PMID: 12138187.
109. Nutt LK, Chandra J, Pataer A, Fang B, Roth JA, Swisher SG, O'Neil RG, McConkey DJ. Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem 277:20301-20308, 6/2002. PMID: 11909872.
110. Agui T, McConkey DJ, Tanigawa N. Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas. Anticancer Res 22:1769-1776, 5/2002. PMID: 12168867.
111. Santamaria AB, Davis DW, Nghiem DX, McConkey DJ, Ullrich SE, Kapoor M, Lozano G, Ananthaswamy HN. p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells. Cell Death Differ 9:549-560, 5/2002. PMID: 11973613.
112. Jung YD, Fan F, McConkey DJ, Jean ME, Liu W, Reinmuth N, Stoeltzing O, Ahmad SA, Parikh AA, Mukaida N, Ellis LM. Role of P38 MAPK, AP-1, and NF-kappaB in interleukin-1beta-induced IL-8 expression in human vascular smooth muscle cells. Cytokine 18:206-213, 5/2002. PMID: 12126643.
113. Bondar VM, McConkey DJ. Anoikis is regulated by BCL-2-independent pathways in human prostate carcinoma cells. Prostate 51:42-49, 4/2002. PMID: 11920957.
114. Nutt LK, Pataer A, Pahler J, Fang B, Roth J, McConkey DJ, Swisher SG. Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem 277:9219-9225, 3/2002. PMID: 11741880.
115. Termuhlen PM, Sweeney-Gotsch BM, Berman RS, Ellis LM, Bucana C, Shen Y, Cleary KR, McConkey DJ. Increased apoptosis in metastatic human colonic adenocarcinomas. Cancer Biol Ther 1:58-63, 2002. PMID: 12170764.
116. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 25:562-568, 11/2001. PMID: 11713097.
117. Solorzano CC, Jung YD, Bucana CD, McConkey DJ, Gallick GE, McMahon G, Ellis LM. In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer Res 61:7048-7051, 10/2001. PMID: 11585733.
118. Bold RJ, Virudachalam S, McConkey DJ. BCL2 expression correlates with metastatic potential in pancreatic cancer cell lines. Cancer 92:1122-1129, 9/2001. PMID: 11571724.
119. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100:11-17, 9/2001. PMID: 11516199.
120. Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res 7:2840-2853, 9/2001. PMID: 11555602.
121. Liu W, Davis DW, Ramirez K, McConkey DJ, Ellis LM. Endothelial cell apoptosis is inhibited by a soluble factor secreted by human colon cancer cells. Int J Cancer 92:26-30, 4/2001. PMID: 11279602.
122. Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon G, Ellis LM. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 61:1464-1468, 2/2001. PMID: 11245452.
123. Nyormoi O, Wang Z, Doan D, Ruiz M, McConkey D, Bar-Eli M. Transcription factor AP-2a is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor a-induced apoptosis in breast cancer cells. Mol Cell Biol 21:4856-4867, 2001.
124. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6:4874-4884, 12/2000. PMID: 11156247.
125. Pathak S, Multani AS, McConkey DJ, Imam AS, Amoss MS, Jr. Spontaneous regression of cutaneous melanoma in sinclair swine is associated with defective telomerase activity and extensive telomere erosion. Int J Oncol 17:1219-1224, 12/2000. PMID: 11078808.
126. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 60:4959-4967, 9/2000. PMID: 10987313.
127. Davis DW, Weidner DA, Holian A, McConkey DJ. Nitric oxide-dependent activation of p53 suppresses bleomycin-induced apoptosis in the lung. J Exp Med 192:857-869, 9/2000. PMID: 10993916.
128. Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89:488-499, 8/2000. PMID: 10931447.
129. McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 60:3807-3812, 7/2000. PMID: 10919654.
130. Multani AS, Ozen M, Narayan S, Kumar V, Chandra J, McConkey DJ, Newman RA, Pathak S. Caspase-dependent apoptosis induced by telomere cleavage and TRF2 loss. Neoplasia 2:339-345, 7/2000. PMID: 11005568.
131. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T, Radinsky R, Dinney CP. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 6:2635-2643, 7/2000. PMID: 10914704.
132. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936-1948, 5/2000. PMID: 10815919.
133. Jean D, Tellez C, Huang S, Davis DW, Bruns CJ, McConkey DJ, Hinrichs SH, Bar-Eli M. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene 19:2721-2730, 5/2000. PMID: 10851072.
134. Watson VE, Hill LL, Owen-Schaub LB, Davis DW, McConkey DJ, Jagannath C, Hunter RL, Jr, Actor JK. Apoptosis in mycobacterium tuberculosis infection in mice exhibiting varied immunopathology. J Pathol 190:211-220, 2/2000. PMID: 10657021.
135. Ouhtit A, Muller HK, Davis DW, Ullrich SE, McConkey D, Ananthaswamy HN. Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. Am J Pathol 156:201-207, 2000.
136. Bruns CJ, Shinohara H, Harbison MT, Davis DW, Nelkin G, Killion JJ, McConkey DJ, Dong Z, Fidler IJ. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages. Cancer Res 60:2-7, 2000. PMID: 10646841.
137. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59:5412-5416, 11/1999. PMID: 10554007.
138. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Hallin PA, Chiao PJ, Abbruzzese JL, Evans DB. Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg 3:263-277, 5/1999. PMID: 10481119.
139. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 6:279-285, 4/1999. PMID: 10340887.
140. Diaz C, Lee AT, McConkey DJ, Schroit AJ. Phosphatidylserine externalization during differentiation-triggered apoptosis of erythroleukemic cells. Cell Death Differ 6:218-226, 3/1999. PMID: 10200572.
141. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59:2551-2556, 1999.
142. Bouvet M, Bold RJ, Lee J, Evans DB, Abbruzzese JL, Chiao PJ, McConkey DJ, Chandra J, Chada S, Fang B, Roth JA. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. Ann Surg Oncol 5:681-688, 12/1998. PMID: 9869513.
143. Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M, McConkey DJ. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92:4220-4229, 12/1998. PMID: 9834227.
144. Jean D, Harbison M, McConkey DJ, Ronai Z, Bar-Eli M. CREB and its associated proteins act as survival factors for human melanoma cells. J Biol Chem 273:24884-14890, 9/1998. PMID: 9733794.
145. Voehringer DW, McConkey DJ, McDonnell TJ, Brisbay S, Meyn RE. Bcl-2 expression causes redistribution of glutathione to the nucleus. Proc Natl Acad Sci U S A 95:2956-2960, 3/1998. PMID: 9501197.
146. Chandra J, Gilbreath J, Freireich EJ, Kliche KO, Andreeff M, Keating M, McConkey DJ. Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. Blood 90:3673-3681, 11/1997. PMID: 9345052.
147. Mirkovic N, Voehringer DW, Story MD, McConkey DJ, McDonnell TJ, Meyn RE. Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene 15:1461-1470, 9/1997. PMID: 9333022.
148. Xie K, Wang Y, Huang S, Xu L, Bielenberg D, Salas T, McConkey DJ, Jiang W, Fidler IJ. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2. Oncogene 15:771-779, 8/1997. PMID: 9266963.
149. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56:5594-5599, 12/1996. PMID: 8971161.
150. Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD, Bar-Eli M. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13:2339-2347, 12/1996. PMID: 8957075.
151. Xie K, Huang S, Wang Y, Beltran PJ, Juang SH, Dong Z, Reed JC, McDonnell TJ, McConkey DJ, Fidler IJ. Bcl-2 protects cells from cytokine-induced nitric-oxide-dependent apoptosis. Cancer Immunol Immunother 43:109-115, 10/1996. PMID: 8954145.
152. McConkey DJ, Goodrich D, Bucana C, Klostergaard J. The human retinoblastoma gene product suppresses ceramide-induced apoptosis in human bladder tumor cells. Oncogene 13:1693-1700, 10/1996. PMID: 8895515.
153. McConkey DJ. Calcium-dependent, interleukin 1-converting enzyme inhibitor-insensitive degradation of lamin B1 and DNA fragmentation in isolated thymocyte nuclei. J Biol Chem 271:22398-22406, 9/1996. PMID: 8798402.
154. Trent JC, McConkey DJ, Loughlin SM, Harbison MT, Fernandez A, Ananthaswamy HN. Ras signaling in tumor necrosis factor-induced apoptosis. Embo J 15:4497-4505, 9/1996. PMID: 8887541.
155. Marin MC, Fernandez A, Bick RJ, Brisbay S, Buja LM, Snuggs M, McConkey DJ, von Eschenbach AC, Keating MJ, McDonnell TJ. Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. Oncogene 12:2259-2266, 6/1996. PMID: 8649765.
156. Warren AP, Patel K, McConkey DJ, Palacios R. CD98: a type II transmembrane glycoprotein expressed from the beginning of primitive and definitive hematopoiesis may play a critical role in the development of hematopoietic cells. Blood 87:3676-3687, 5/1996. PMID: 8611692.
157. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating M. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 156:2624-2630, 4/1996. PMID: 8786328.
158. Gossett R, Kier AB, Schroeder F, McConkey D, Fadok V, Amoss MS, Jr. Cycloheximide-induced apoptosis in melanoma cells derived from regressing cutaneous tumours of Sinclair swine. J Comp Pathol 115:353-372, 1996.
159. Xue Y, Murdjeva M, Okret S, McConkey D, Kiuossis D, Jondal M. Inhibition of I-Ad-, but not Db-restricted peptide-induced thymic apoptosis by glucocorticoid receptor antagonist RU486 in T cell receptor transgenic mice. Eur J Immunol 26:428-434, 1996.
160. Fernandez A, Kiefer J, Fosdick L, McConkey DJ. Oxygen radical production and thiol depletion are required for Ca(2+)-mediated endogenous endonuclease activation in apoptotic thymocytes. J Immunol 155:5133-5139, 12/1995. PMID: 7594522.
161. Kiefer J, Okret S, Jondal M, McConkey DJ. Functional glucocorticoid receptor expression is required for cAMP-mediated apoptosis in a human leukemic T cell line. J Immunol 155:4525-4528, 11/1995. PMID: 7594448.
162. McConkey DJ, Fernandez A, Trent J, 2nd, Ananthaswamy HN. Oncogene regulation of endonuclease activation in apoptosis. Cancer Lett 94:9-16, 7/1995. PMID: 7621450.
163. Neamati N, Fernandez A, Wright S, Kiefer J, McConkey DJ. Degradation of lamin B1 precedes oligonucleosomal DNA fragmentation in apoptotic thymocytes and isolated thymocyte nuclei. J Immunol 154:3788-3795, 4/1995. PMID: 7535814.
164. Fernandez A, Fosdick LJ, Marin MC, Diaz C, McDonnell TJ, Ananthaswamy HN, McConkey DJ. Differential regulation of endogenous endonuclease activation in isolated murine fibroblast nuclei by ras and bcl-2. Oncogene 10:769-774, 2/1995. PMID: 7862455.
165. McConkey DJ, Orrenius S. Calcium and cyclosporin A in the regulation of apoptosis. Curr Top Microbiol Immunol 200:95-105, 1995. PMID: 7634840.
166. McConkey DJ, Fosdick L, D'Adamio L, Jondal M, Orrenius S. Co-receptor (CD4/CD8) engagement enhances CD3-induced apoptosis in thymocytes. Implications for negative selection. J Immunol 153:2436-2443, 9/1994. PMID: 8077659.
167. McConkey DJ, Orrenius S, Okret S, Jondal M. Cyclic AMP potentiates glucocorticoid-induced endogenous endonuclease activation in thymocytes. Faseb J 7:580-585, 4/1993. PMID: 8386120.
168. Hussey RE, Clayton LK, Diener A, McConkey DJ, Howard FD, Rodewald HR, D'Adamio L, Dallenbach F, Stein H, Schmidt EV, Koyasu S, Reinherz EL. Overexpression of CD3 eta during thymic development does not alter the negative selection process. J Immunol 150:1183-1194, 2/1993. PMID: 8094404.
169. Moingeon P, Rodewald HR, McConkey D, Mildonian A, Awad K, Reinherz EL. Generation of natural killer cells from both Fc gamma RII/III+ and Fc gamma RII/III-murine fetal liver progenitors. Blood 82:1453-1462, 1993.
170. Jondal M, Okret S, McConkey D. Killing of immature CD4+ CD8+ thymocytes in vivo by anti-CD3 or 5'-(N-ethyl)-carboxamide adenosine is blocked by glucocorticoid receptor antagonist RU-486. Eur J Immunol 23:1246-1250, 1993.
171. Howard FD, Moingeon P, Moebius U, McConkey DJ, Yandava B, Gennert TE, Reinherz EL. The CD3 zeta cytoplasmic domain mediates CD2-induced T cell activation. J Exp Med 176:139-145, 7/1992. PMID: 1351920.
172. Moingeon P, Lucich JL, McConkey DJ, Letourneur F, Malissen B, Kochan J, Chang HC, Rodewald HR, Reinherz EL. CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells. Proc Natl Acad Sci U S A 89:1492-1496, 2/1992. PMID: 1346934.
173. Koyasu S, McConkey DJ, Clayton LK, Abraham S, Yandava B, Katagiri T, Moingeon P, Yamamoto T, Reinherz EL. Phosphorylation of multiple CD3 zeta tyrosine residues leads to formation of pp21 in vitro and in vivo. Structural changes upon T cell receptor stimulation. J Biol Chem 267:3375-3381, 2/1992. PMID: 1531339.
174. Bauer A, McConkey DJ, Howard FD, Clayton LK, Novick D, Koyasu S, Reinherz EL. Differential signal transduction via T-cell receptor CD3 zeta 2, CD3 zeta-eta, and CD3 eta 2 isoforms. Proc Natl Acad Sci U S A 88:3842-3846, 5/1991. PMID: 1708889.
175. McConkey DJ, Aguilar-Santelises M, Hartzell P, Eriksson I, Mellstedt H, Orrenius S, Jondal M. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol 146:1072-1076, 2/1991. PMID: 1988495.
176. McConkey DJ, Orrenius S, Jondal M. Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. J Immunol 145:1227-1230, 8/1990. PMID: 2166110.
177. McConkey DJ, Chow SC, Orrenius S, Jondal M. NK cell-induced cytotoxicity is dependent on a Ca2+ increase in the target. Faseb J 4:2661-2664, 6/1990. PMID: 2347464.
178. McConkey DJ, Hartzell P, Orrenius S. Rapid turnover of endogenous endonuclease activity in thymocytes: effects of inhibitors of macromolecular synthesis. Arch Biochem Biophys 278:284-287, 4/1990. PMID: 2157360.
179. McConkey DJ, Hartzell P, Chow SC, Orrenius S, Jondal M. Interleukin 1 inhibits T cell receptor-mediated apoptosis in immature thymocytes. J Biol Chem 265:3009-3011, 2/1990. PMID: 2105939.
180. Perotti M, Toddei F, Mirabelli F, Vairetti M, Bellomo G, McConkey DJ, Orrenius S. Calcium-dependent DNA fragmentation in human synovial cells exposed to cold shock. FEBS Lett 259:331-334, 1990. PMID: 2152884.
181. Chow SC, McConkey DJ, Orrenius S, Jondal M. Quantitation of DNA fragmentation using fiberglass filters. Anal Biochem 183:42-45, 11/1989. PMID: 2619047.
182. McConkey DJ, Hartzell P, Amador-Perez JF, Orrenius S, Jondal M. Calcium-dependent killing of immature thymocytes by stimulation via the CD3/T cell receptor complex. J Immunol 143:1801-1806, 9/1989. PMID: 2528581.
183. McConkey DJ, Hartzell P, Jondal M, Orrenius S. Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. J Biol Chem 264:13399-13402, 8/1989. PMID: 2503500.
184. McConkey DJ, Orrenius S. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) kills glucocorticoid-sensitive thymocytes in vivo. Biochem Biophys Res Commun 160:1003-1008, 5/1989. PMID: 2543382.
185. McConkey DJ, Hartzell P, Nicotera P, Orrenius S. Calcium-activated DNA fragmentation kills immature thymocytes. Faseb J 3:1843-1849, 5/1989. PMID: 2497041.
186. Jones DP, McConkey DJ, Nicotera P, Orrenius S. Calcium-activated DNA fragmentation in rat liver nuclei. J Biol Chem 264:6398-6403, 4/1989. PMID: 2703497.
187. McConkey DJ, Nicotera P, Hartzell P, Bellomo G, Wyllie AH, Orrenius S. Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca2+ concentration. Arch Biochem Biophys 269:365-370, 2/1989. PMID: 2537063.
188. Nicotera P, McConkey DJ, Jones DP, Orrenius S. ATP stimulates Ca2+ uptake and increases the free Ca2+ concentration in isolated rat liver nuclei. Proc Natl Acad Sci U S A 86:453-457, 1989. PMID: 2911591.
189. McConkey DJ, Hartzell P, Duddy SK, Hakansson H, Orrenius S. 2,3,7,8-Tetrachlorodibenzo-p-dioxin kills immature thymocytes by Ca2+-mediated endonuclease activation. Science 242:256-259, 10/1988. PMID: 3262923.
190. McConkey DJ, Hartzell P, Nicotera P, Wyllie AH, Orrenius S. Stimulation of endogenous endonuclease activity in hepatocytes exposed to oxidative stress. Toxicol Lett 42:123-230, 8/1988. PMID: 2841775.
191. Nicotera P, McConkey D, Svensson SA, Bellomo G, Orrenius S. Correlation between cytosolic Ca2+ concentration and cytotoxicity in hepatocytes exposed to oxidative stress. Toxicology 52:55-63, 1988.
192. Moore GA, McConkey DJ, Kass GE, O'Brien PJ, Orrenius S. 2,5-Di(tert-butyl)-1,4-benzohydroquinone--a novel inhibitor of liver microsomal Ca2+ sequestration. FEBS Lett 224:331-336, 11/1987. PMID: 2961610.
193. McConkey DJ, Crankshaw DL, Holtzman JL. Glucagon activation of the thiol:protein disulfide oxidoreductase in isolated, rat, hepatic microsomes. Life Sci 38:2139-2143, 6/1986. PMID: 3520201.
194. Fournier K, Marquis L, Choi W, Kwan A, McConkey DJ. Histone deacetylase (HDAC) inhibitors reverse EMT and resistance to EGFR inhibitors and gemcitabine in human pancreatic cancer cells. Mol Cancer Ther. Submitted.
195. Qi W, White M, McConkey DJ, Siefker-Radtke A. Suppression of HSP72 enhances bortezomib-induced cell death in bladder cancer. Cancer Res. Submitted.

Grant & Contract Support

Title: Personalized Therapy of Bladder Cancer
Funding Source: Dexter F. & Dorothy Baker Foundation
Role: Principal Investigator
Duration: 6/1/2012 - 5/31/2014
 
Title: Targeting ER Stress for Pancreatic Cancer Therapeutics
Funding Source: Viragh Foundation
Role: Co-Principal Investigator
Duration: 1/10/2012 - 12/31/2015
 
Title: Targeted Therapy in Bladder Cancer
Funding Source: AstraZeneca
Role: Principal Investigator
Duration: 1/10/2010 - 12/31/2010
 
Title: Biology and Therapeutic Targeting of the Epidermal Growth Receptor
Funding Source: NIH/NCI
Role: Co-Director
Duration: 9/1/2009 - 8/31/2013
 
Title: Death Receptors in Bladder Cancer Progression and Therapy
Funding Source: NIH/NCI
Role: Laboratory Co-Leader
Duration: 9/1/2009 - 8/31/2013
 
Title: M. D. Anderson SPORE in Genitourinary Cancer
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 9/1/2009 - 8/31/2013
 
Title: Proteasome inhibition and ER stress
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 1/2009 - 11/2013
 
Title: Preclinical evaluation of targeted therapy in bladder cancer.
Funding Source: M. D. Anderson - Astra Zeneca Alliance
Role: Co-Investigator
Duration: 1/1/2008 - 12/31/2009
 
Title: Cell Cycle Dependence of TRAIL Sensitivity in Prostate Cancer Cells
Funding Source: Department of Defense Prostate Cancer Research Program
Role: Principal Investigator
Duration: 1/1/2005 - 12/31/2008

Last updated: 6/23/2014